|
TSCAN Therapeutics, Inc. (TCRX) Valoración de DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
TScan Therapeutics, Inc. (TCRX) Bundle
¡Mejore sus opciones de inversión con la calculadora DCF de TSCAN Therapeutics, Inc. (TCRX)! Explore datos financieros reales, ajuste las predicciones y gastos de crecimiento, y visualice instantáneamente cómo estos cambios afectan el valor intrínseco de TSCAN Therapeutics, Inc. (TCRX).
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | 1.1 | 10.1 | 13.5 | 21.0 | 31.0 | 45.6 | 67.2 | 98.9 | 145.7 |
| Revenue Growth, % | 0 | 0 | 834.65 | 33.47 | 55.52 | 47.25 | 47.25 | 47.25 | 47.25 | 47.25 |
| EBITDA | -13.7 | -25.0 | -45.3 | -59.9 | -80.1 | -18.6 | -27.4 | -40.3 | -59.4 | -87.4 |
| EBITDA, % | 100 | -2304.42 | -446.67 | -442.62 | -380.53 | -60 | -60 | -60 | -60 | -60 |
| Depreciation | .5 | 1.2 | 3.3 | 5.1 | 5.4 | 18.4 | 27.0 | 39.8 | 58.6 | 86.3 |
| Depreciation, % | 100 | 113.36 | 32.82 | 37.95 | 25.47 | 59.25 | 59.25 | 59.25 | 59.25 | 59.25 |
| EBIT | -14.2 | -26.2 | -48.6 | -65.0 | -85.5 | -18.6 | -27.4 | -40.3 | -59.4 | -87.4 |
| EBIT, % | 100 | -2417.79 | -479.49 | -480.57 | -406 | -60 | -60 | -60 | -60 | -60 |
| Total Cash | 41.8 | 34.8 | 161.4 | 120.0 | 192.0 | 31.0 | 45.6 | 67.2 | 98.9 | 145.7 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | 6.2 | 9.1 | 13.4 | 19.8 | 29.1 |
| Account Receivables, % | 100 | 0 | 0 | 0 | 0 | 20 | 20 | 20 | 20 | 20 |
| Inventories | .0 | .0 | .0 | .0 | .0 | 6.2 | 9.1 | 13.4 | 19.8 | 29.1 |
| Inventories, % | 100 | 0 | 0 | 0 | 0 | 20 | 20 | 20 | 20 | 20 |
| Accounts Payable | 1.0 | 2.9 | 1.8 | 2.9 | 2.4 | 15.5 | 22.8 | 33.6 | 49.5 | 72.9 |
| Accounts Payable, % | 100 | 268.2 | 17.4 | 21.51 | 11.28 | 50.04 | 50.04 | 50.04 | 50.04 | 50.04 |
| Capital Expenditure | -1.2 | -4.2 | -9.9 | -4.2 | -3.1 | -15.1 | -22.3 | -32.8 | -48.3 | -71.2 |
| Capital Expenditure, % | 100 | -390.6 | -98.03 | -31.22 | -14.95 | -48.84 | -48.84 | -48.84 | -48.84 | -48.84 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -13.6 | -26.1 | -48.6 | -64.6 | -85.5 | -18.4 | -27.1 | -39.9 | -58.8 | -86.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -13.4 | -27.2 | -56.4 | -62.6 | -83.8 | -14.4 | -20.9 | -30.7 | -45.3 | -66.7 |
| WACC, % | 6.92 | 6.97 | 6.98 | 6.97 | 6.98 | 6.96 | 6.96 | 6.96 | 6.96 | 6.96 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -139.1 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -68 | |||||||||
| Terminal Value | -1,370 | |||||||||
| Present Terminal Value | -979 | |||||||||
| Enterprise Value | -1,118 | |||||||||
| Net Debt | -41 | |||||||||
| Equity Value | -1,077 | |||||||||
| Diluted Shares Outstanding, MM | 66 | |||||||||
| Equity Value Per Share | -16.41 |
What You Will Get
- Editable Forecast Inputs: Easily modify key assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: TScan Therapeutics, Inc.'s (TCRX) financial data pre-filled to facilitate your analysis.
- Automatic DCF Outputs: The template automatically calculates Net Present Value (NPV) and intrinsic value for your convenience.
- Customizable and Professional: A sleek Excel model designed to meet your valuation requirements.
- Built for Analysts and Investors: Perfect for assessing projections, validating strategies, and enhancing efficiency.
Key Features
- Comprehensive TCRX Data: Pre-loaded with TScan Therapeutics’ historical performance metrics and future growth projections.
- Highly Customizable Variables: Modify assumptions on revenue growth, profit margins, discount rates, tax implications, and capital investments.
- Interactive Valuation Framework: Instantly recalculates Net Present Value (NPV) and intrinsic value based on your specified parameters.
- Multiple Scenario Analysis: Develop various forecasting scenarios to explore different valuation results.
- Intuitive User Interface: Designed for ease of use, catering to both industry experts and newcomers.
How It Works
- Download the Template: Gain immediate access to the Excel-based TScan Therapeutics, Inc. (TCRX) DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other variables.
- Instant Calculations: The model will automatically refresh TScan’s intrinsic value.
- Test Scenarios: Experiment with different assumptions to assess potential changes in valuation.
- Analyze and Decide: Utilize the outcomes to inform your investment or financial strategy.
Why Choose This Calculator?
- Accurate Data: Real TScan Therapeutics financials ensure reliable valuation results.
- Customizable: Adjust key parameters like growth rates, WACC, and tax rates to match your projections.
- Time-Saving: Pre-built calculations eliminate the need to start from scratch.
- Professional-Grade Tool: Designed for investors, analysts, and consultants.
- User-Friendly: Intuitive layout and step-by-step instructions make it easy for all users.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling TScan Therapeutics, Inc. (TCRX) stock.
- Financial Analysts: Streamline valuation processes with ready-to-use financial models specific to TScan Therapeutics, Inc. (TCRX).
- Consultants: Provide clients with professional valuation insights on TScan Therapeutics, Inc. (TCRX) swiftly and accurately.
- Business Owners: Gain insights into how biotech companies like TScan Therapeutics, Inc. (TCRX) are valued to inform your own business strategy.
- Finance Students: Explore valuation techniques using real-world data and scenarios related to TScan Therapeutics, Inc. (TCRX).
What the Template Contains
- Preloaded TCRX Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.